TABLE 2.
Logistic regression analysis for long‐term response defined as more than 6 months progression free survival and ICI therapy continuation
| Covariate | n | Univariable analysis | Multivariable analysis | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 95% CI | 95% CI | ||||||||
| HR | Lower | Upper | p value | HR | Lower | Upper | p value | ||
| Gender (male) | 98 | 1.48 | 0.43 | 5.05 | 0.53 | ||||
| Age | 98 | 0.99 | 0.94 | 1.04 | 0.68 | ||||
| WHO PS 1 or 2 compared to WHO PS 0 | 98 | 0.23 | 0.09 | 0.57 | 0.001 | 0.16 | 0.04 | 0.54 | 0.003 |
| CCI 7 or higher compared to CCI <7 | 98 | 1.78 | 0.71 | 4.43 | 0.22 | ||||
| Distant metastatic disease versus recurrent only | 98 | 2.32 | 0.88 | 6.14 | 0.09 | ||||
| P16+/HPV+ oropharyngeal tumors | 92 | 1.47 | 0.47 | 4.60 | 0.51 | ||||
| PD‐L1 expression | |||||||||
| Low (CPS <1) | 22 | 0.10 | |||||||
| Intermediate (CPS 1–19) | 36 | 4.52 | 1.13 | 18.09 | 0.03 | ||||
| High (CPS ≥20) | 21 | 3.17 | 0.69 | 14.46 | 0.14 | ||||
| Second line or higher palliative systemic therapy | 98 | 0.75 | 0.32 | 1.75 | 0.51 | ||||
| Platinum refractory | 98 | 0.94 | 0.42 | 2.24 | 0.94 | ||||
| Weight loss in 6 months prior to ICI (%, continuous) | 87 | 0.98 | 0.96 | 1.01 | 0.29 | ||||
| Cachexia and weight loss >2% during 6 weeks ICI (ref) | 15 | 0.14 | |||||||
| Cachexia and stable weight during 6 weeks ICI | 24 | 10.00 | 1.13 | 88.91 | 0.04 | ||||
| No cachexia and weight loss >2% during 6 weeks ICI | 15 | 5.09 | 0.50 | 52.29 | 0.17 | ||||
| No cachexia and stable weight during 6 weeks ICI | 33 | 10.32 | 1.21 | 87.94 | 0.03 | ||||
| Catabolic category versus others | 87 | 0.11 | 0.01 | 0.90 | 0.04 | ||||
| BMI | 98 | 1.19 | 1.06 | 1.34 | 0.003 | ||||
| SMI | 98 | 1.07 | 1.01 | 1.13 | 0.02 | ||||
| VAT index | 98 | 1.02 | 1.002 | 1.04 | 0.03 | ||||
| SAT index | 94 | 1.03 | 1.01 | 1.05 | 0.002 | 1.05 | 1.02 | 1.08 | 0.003 |
| Low SMI | 98 | 0.76 | 0.33 | 1.76 | 0.52 | ||||
| Cachexia | 87 | 0.66 | 0.26 | 1.63 | 0.36 | ||||
| Weight loss during first 6 weeks of ICI (%, continuous) | 98 | 0.89 | 0.80 | 0.99 | 0.03 | 0.85 | 0.74 | 0.98 | 0.03 |
| NLR | 93 | 0.94 | 0.80 | 1.10 | 0.41 | ||||
| PLR | 93 | 1.00 | 1.00 | 1.00 | 0.92 | ||||
| Albumin | 94 | 1.11 | 0.99 | 1.24 | 0.07 | ||||
Note: All variables are considered at baseline (start ICI) unless reported otherwise. Bold values denote statistical significance at the p < 0.05 level.
Abbreviations: BMI, body mass index; catabolic category is defined as the group of patients with cachexia at baseline and further weight loss >2% during 6 weeks immune checkpoint inhibitors; CCI, Charlson Comorbidity Index; ICI, immune checkpoint inhibitors; NLR, neutrophil‐lymphocyte ratio; PLR, platelet‐lymphocyte ratio; SAT, subcutaneous adipose tissue; SMI, skeletal muscle index; VAT, visceral adipose tissue; WHO PS, world health organization performance status.